Novo, Eli Lilly to dominate global pharma sales in 2025: report
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
GlobalData on MSN21h
Novo Nordisk and Valo expand cardiometabolic drug partnership
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
manilatimes21h
Top 2 Best Places to Work in Indonesia for 2024 announced
JAKARTA, INDONESIA - Media OutReach Newswire - 9 January 2025 - Novo Nordisk and AstraZeneca have been recognized as the top ...
GEN1d
Novo Nordisk, Valo Health Ink Expanded Up-to-$4.6B AI Collaboration
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
Becker's Hospital Review1d
Novo Nordisk joins Eli Lilly in legal challenge over GLP-1 compounding
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...
Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, Abbvie, And Sanofi
The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...